Nanoparticle albumin-bound paclitaxel and ramucirumab versus paclitaxel and ramucirumab as second-line chemotherapy for unresectable advanced or recurrent gastric cancer: a multicenter, propensity score-matched analysis (CROSS SELL study)

被引：0
作者：
Akio Nakasya
Yuya Hagiwara
Tatsuki Ikoma
Yusuke Kurioka
Toshihiko Matsumoto
Yoshiyuki Yamamoto
Takao Tsuduki
Takeshi Kajiwara
Toshikazu Moriwaki
Tomohiro Nishina
Natsumi Yamashita
Ichinosuke Hyodo
机构：
[1] National Hospital Organization Shikoku Cancer Center,Department of Gastrointestinal Medical Oncology
[2] University of Tsukuba,Department of Gastroenterology, Faculty of Medicine
[3] Kobe City Medical Center General Hospital,Department of Medical Oncology
[4] Himeji Red Cross Hospital,Department of Internal Medicine
[5] National Hospital Organization Shikoku Cancer Center,Section of Cancer Prevention and Epidemiology, Clinical Research Center
来源：
International Journal of Clinical Oncology | 2022年 / 27卷
关键词：
Gastric cancer; Chemotherapy; Albumin-bound paclitaxel; Paclitaxel; Ramucirumab; Propensity score;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：684 / 694
页数：10
相关论文
共 50 条
  • [31] Ramucirumab plus paclitaxel as a second-line treatment in HER2-positive gastric cancer: subgroup analysis of a nationwide, real-world study in Korea (KCSG-ST19-16)
    Kim, Bum Jun
    Jee, Hee-Jung
    Rha, Sun Young
    Han, Hye Sook
    Ryu, Min-Hee
    Park, Se Hoon
    Kim, Jong Gwang
    Bae, Woo Kyun
    Lee, Keun-Wook
    Oh, Do-Youn
    Byun, Ji-Hye
    Kim, Dong Sook
    Suh, Young Ju
    An, Hyonggin
    Zang, Dae Young
    GASTRIC CANCER, 2022, 25 (03) : 609 - 618
  • [32] Weekly paclitaxel plus ramucirumab versus weekly nab-paclitaxel plus ramucirumab for unresectable advanced or recurrent gastric cancer with peritoneal dissemination refractory to first-line therapy—the P-SELECT trial (WJOG10617G)—a randomised phase II trial by the West Japan Oncology Group
    Kenro Hirata
    Yasuo Hamamoto
    Masahiko Ando
    Chiyo K. Imamura
    Kenichi Yoshimura
    Kentaro Yamazaki
    Shuichi Hironaka
    Kei Muro
    BMC Cancer, 20
  • [33] The relationship between peripheral neuropathy and efficacy in second-line chemotherapy for unresectable advanced gastric cancer: a prospective observational multicenter study protocol (IVY)
    Hiroaki Tanioka
    Takeshi Nagasaka
    Futoshi Uno
    Masafumi Inoue
    Hiroyuki Okita
    Yosuke Katata
    Hiromitsu Kanzaki
    Hidekazu Kuramochi
    Hironaga Satake
    Yoshiaki Shindo
    Akira Doi
    Jyunichiro Nasu
    Haruhiro Yamashita
    Yoshiyuki Yamaguchi
    BMC Cancer, 19
  • [34] Real-World Outcomes of Gemcitabine, Cisplatin, and Nab-Paclitaxel Chemotherapy Regimen for Advanced Biliary Tract Cancer: A Propensity Score-Matched Analysis
    Jung, Kwangrok
    Park, Jaewoo
    Jung, Jae Hyup
    Lee, Jong-Chan
    Kim, Jaihwan
    Hwang, Jin-Hyeok
    GUT AND LIVER, 2022, 16 (05) : 798 - 805
  • [35] Nanoparticle albumin-bound paclitaxel with cetuximab and carboplatin as first-line therapy for recurrent or metastatic head and neck cancer: A single-arm, multicenter, phase 2 trial*
    Adkins, Douglas
    Ley, Jessica
    Atiq, Omar
    Powell, Steven
    Spanos, William C.
    Gitau, Mark
    Rigden, Caron
    Palka, Kevin
    Liu, Jingxia
    Oppelt, Peter
    ORAL ONCOLOGY, 2021, 115
  • [36] Nab-paclitaxel as second-line treatment in advanced gastric cancer: a multicenter phase II study of the Hellenic Oncology Research Group
    Katsaounis, Panagiotis
    Kotsakis, Athanasios
    Kentepozidis, Nikolaos
    Polyzos, Aris
    Bakogeorgos, Marios
    Koinis, Filippos
    Vamvakas, Lambros
    Vardakis, Nikolaos
    Kalbakis, Kostas
    Boukovinas, Ioannis
    Varthalitis, Ioannis I.
    Prinarakis, Efthimios
    Georgoulias, Vassilis
    Souglakos, John
    ANNALS OF GASTROENTEROLOGY, 2018, 31 (01): : 65 - 70
  • [37] Analysis of the efficacy and safety of paclitaxel (albumin-bound) combined with S-1 and oxaliplatin combined with S-1 in the first- line treatment of advanced gastric cancer: a cohort study
    Ma, Jian
    Xiao, Min
    Li, Xiaoqian
    Zhao, Qiu
    Ji, Wenjing
    Ling, Yang
    Yang, Quanliang
    JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2022, 13 (02) : 630 - 636
  • [38] Second-line chemoimmunotherapy with nivolumab and paclitaxel in immune-related biomarker-enriched advanced gastric cancer: a multicenter phase Ib/II study
    Choong-kun Lee
    Jii Bum Lee
    Se Jung Park
    Jingmin Che
    Woo Sun Kwon
    Hyo Song Kim
    Minkyu Jung
    Seulkee Lee
    Sook Ryun Park
    Dong-Hoe Koo
    Hyun Woo Lee
    Woo Kyun Bae
    Hei-Cheul Jeung
    In Gyu Hwang
    Hyunki Kim
    Chung Mo Nam
    Hyun Cheol Chung
    Sun Young Rha
    Gastric Cancer, 2024, 27 : 118 - 130
  • [39] Second-line chemoimmunotherapy with nivolumab and paclitaxel in immune-related biomarker-enriched advanced gastric cancer: a multicenter phase Ib/II study
    Lee, Choong-kun
    Lee, Jii Bum
    Park, Se Jung
    Che, Jingmin
    Kwon, Woo Sun
    Kim, Hyo Song
    Jung, Minkyu
    Lee, Seulkee
    Park, Sook Ryun
    Koo, Dong-Hoe
    Lee, Hyun Woo
    Bae, Woo Kyun
    Jeung, Hei-Cheul
    Hwang, In Gyu
    Kim, Hyunki
    Nam, Chung Mo
    Chung, Hyun Cheol
    Rha, Sun Young
    GASTRIC CANCER, 2024, 27 (01) : 118 - 130
  • [40] Lapatinib Plus Paclitaxel Versus Paclitaxel Alone in the Second-Line Treatment of HER2-Amplified Advanced Gastric Cancer in Asian Populations: TyTANA- A Randomized, Phase III Study
    Satoh, Taroh
    Xu, Rui-Hua
    Chung, Hyun Cheol
    Sun, Guo-Ping
    Doi, Toshihiko
    Xu, Jian-Ming
    Tsuji, Akihito
    Omuro, Yasushi
    Li, Jin
    Wang, Jin-Wan
    Miwa, Hiroto
    Qin, Shu-Kui
    Chung, Ik-Joo
    Yeh, Kun-Huei
    Feng, Ji-Feng
    Mukaiyama, Akihira
    Kobayashi, Mikiro
    Ohtsu, Atsushi
    Bang, Yung-Jue
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (19) : 2039 - U89
12345